Literature DB >> 29298890

Full-Length Glycosylated Gag of Murine Leukemia Virus Can Associate with the Viral Envelope as a Type I Integral Membrane Protein.

Tyler Milston Renner1, Kasandra Bélanger1, Cindy Lam1, María Carla Rosales Gerpe1, Joanne Eileen McBane1, Marc-André Langlois2.   

Abstract

The glycosylated Gag protein (gPr80) of murine leukemia viruses (MLVs) has been shown to exhibit multiple roles in facilitating retrovirus release, infection, and resistance to host-encoded retroviral restriction factors, such as APOBEC3, SERINC3, and SERINC5. One way in which gPr80 helps MLVs to escape host innate immune restriction is by increasing capsid stability, a feature that protects viral replication intermediates from being detected by cytosolic DNA sensors. gPr80 also increases the resistance of MLVs to deamination and restriction by mouse APOBEC3 (mA3). How the gPr80 accessory protein, with its three N-linked glycosylation sites, contributes to these resistance mechanisms is still not fully understood. Here we further characterized the function of gPr80 and, more specifically, revealed that the asparagines targeted for glycosylation in gPr80 also contribute to capsid stability through their parallel involvement in the Pr65 Gag structural polyprotein. In fact, we demonstrate that sensitivity to deamination by the mA3 and human A3 proteins is directly linked to capsid stability. We also show that full-length gPr80 is detected in purified viruses. However, our results suggest that gPr80 is inserted in the NexoCcyto orientation of a type I integral membrane protein. Additionally, our experiments have revealed the existence of a large population of Env-deficient virus-like particles (VLPs) harboring gPr80 inserted in the opposite (NcytoCexo) polarity, which is typical of type II integral membrane proteins. Overall this study provides new insight into the complex nature of the MLV gPr80 accessory protein.IMPORTANCE Viruses have evolved numerous strategies to infect, spread in, and persist in their hosts. Here we analyze the details of how the MLV-encoded glycosylated Gag (gPr80) protein protects the virus from being restricted by host innate immune defenses. gPr80 is a variant of the structural Pr65 Gag protein with an 88-amino-acid extended leader sequence that directs the protein for translation and glycosylation in the endoplasmic reticulum. This study dissects the specific contributions of gPr80 glycans and capsid stability in helping the virus to infect cells, spread, and counteract the effects of the host intrinsic restriction factor APOBEC3. Overall this study provides further insight into the elusive role of the gPr80 protein.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  APOBEC3; MLV; SERINC3; SERINC5; glyco-Gag

Mesh:

Substances:

Year:  2018        PMID: 29298890      PMCID: PMC5827372          DOI: 10.1128/JVI.01530-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  The Nef-like effect of murine leukemia virus glycosylated gag on HIV-1 infectivity is mediated by its cytoplasmic domain and depends on the AP-2 adaptor complex.

Authors:  Yoshiko Usami; Sergei Popov; Heinrich G Göttlinger
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

Review 2.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

3.  Characterization of glycosylated Gag expressed by a neurovirulent murine leukemia virus: identification of differences in processing in vitro and in vivo.

Authors:  R Fujisawa; F J McAtee; J H Zirbel; J L Portis
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Deamination intensity profiling of human APOBEC3 protein activity along the near full-length genomes of HIV-1 and MoMLV by HyperHRM analysis.

Authors:  Kasandra Bélanger; Mathieu Savoie; Halil Aydin; Tyler Milston Renner; Zahra Montazeri; Marc-André Langlois
Journal:  Virology       Date:  2013-10-25       Impact factor: 3.616

5.  A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses.

Authors:  A Corbin; A C Prats; J L Darlix; M Sitbon
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

6.  Species-specific restriction of apobec3-mediated hypermutation.

Authors:  Edward P Browne; Dan R Littman
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

7.  gag-Related polyproteins of Moloney murine leukemia virus: evidence for independent synthesis of glycosylated and unglycosylated forms.

Authors:  S A Edwards; H Fan
Journal:  J Virol       Date:  1979-05       Impact factor: 5.103

8.  Murine leukemia virus (MLV) replication monitored with fluorescent proteins.

Authors:  Katja Sliva; Otto Erlwein; Alexandra Bittner; Barbara S Schnierle
Journal:  Virol J       Date:  2004-12-20       Impact factor: 4.099

9.  The N-terminus of murine leukaemia virus p12 protein is required for mature core stability.

Authors:  Darren J Wight; Virginie C Boucherit; Madushi Wanaguru; Efrat Elis; Elizabeth M A Hirst; Wilson Li; Marcelo Ehrlich; Eran Bacharach; Kate N Bishop
Journal:  PLoS Pathog       Date:  2014-10-30       Impact factor: 6.823

10.  Functional Interplay Between Murine Leukemia Virus Glycogag, Serinc5, and Surface Glycoprotein Governs Virus Entry, with Opposite Effects on Gammaretroviral and Ebolavirus Glycoproteins.

Authors:  Yadvinder S Ahi; Shu Zhang; Yashna Thappeta; Audrey Denman; Amin Feizpour; Suryaram Gummuluru; Bjoern Reinhard; Delphine Muriaux; Matthew J Fivash; Alan Rein
Journal:  mBio       Date:  2016-11-22       Impact factor: 7.867

View more
  11 in total

1.  Intact Viral Particle Counts Measured by Flow Virometry Provide Insight into the Infectivity and Genome Packaging Efficiency of Moloney Murine Leukemia Virus.

Authors:  Tyler Milston Renner; Vera A Tang; Dylan Burger; Marc-André Langlois
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

2.  Murine Leukemia Virus P50 Protein Counteracts APOBEC3 by Blocking Its Packaging.

Authors:  Wenming Zhao; Charbel Akkawi; Marylène Mougel; Susan R Ross
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

3.  Deaminase-Dead Mouse APOBEC3 Is an In Vivo Retroviral Restriction Factor.

Authors:  Spyridon Stavrou; Wenming Zhao; Kristin Blouch; Susan R Ross
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

4.  Retroviral Capsid Core Stability Assay.

Authors:  Tyler Milston Renner; Kasandra Bélanger; Marc-André Langlois
Journal:  Bio Protoc       Date:  2018-09-20

5.  Selective Isolation of Retroviruses from Extracellular Vesicles by Intact Virion Immunoprecipitation.

Authors:  Tyler Milston Renner; Kasandra Bélanger; Marc-André Langlois
Journal:  Bio Protoc       Date:  2018-09-05

6.  Murine Leukemia Virus Glycosylated Gag Reduces Murine SERINC5 Protein Expression at Steady-State Levels via the Endosome/Lysosome Pathway to Counteract SERINC5 Antiretroviral Activity.

Authors:  Sunan Li; Iqbal Ahmad; Jing Shi; Bin Wang; Changqing Yu; Lixin Zhang; Yong-Hui Zheng
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

7.  SERINC5 Potently Restricts Retrovirus Infection In Vivo.

Authors:  Uddhav Timilsina; Supawadee Umthong; Brian Lynch; Aimee Stablewski; Spyridon Stavrou
Journal:  mBio       Date:  2020-07-14       Impact factor: 7.867

8.  Characterization of Endogenous SERINC5 Protein as Anti-HIV-1 Factor.

Authors:  Vânia Passos; Thomas Zillinger; Nicoletta Casartelli; Amelie S Wachs; Shuting Xu; Angelina Malassa; Katja Steppich; Hildegard Schilling; Sergej Franz; Daniel Todt; Eike Steinmann; Kathrin Sutter; Ulf Dittmer; Jens Bohne; Olivier Schwartz; Winfried Barchet; Christine Goffinet
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

Review 9.  Mouse APOBEC3 Restriction of Retroviruses.

Authors:  Karen Salas-Briceno; Wenming Zhao; Susan R Ross
Journal:  Viruses       Date:  2020-10-27       Impact factor: 5.048

Review 10.  Foamy Viruses, Bet, and APOBEC3 Restriction.

Authors:  Ananda Ayyappan Jaguva Vasudevan; Daniel Becker; Tom Luedde; Holger Gohlke; Carsten Münk
Journal:  Viruses       Date:  2021-03-18       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.